FMP
Oyster Point Pharma, Inc.
OYST
NASDAQ
Inactive Equity
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
11.17 USD
0 (0%)
OYST Financial Statements
Year
2021
2020
2019
2018
Total Revenue
24.54M
0
0
0
Cost of Revenue
1.52M
0
0
0
Gross Profit
23.01M
0
0
0
Operating Expenses
119.67M
70.99M
47.3M
16.74M
Research and Development
24.23M
39.81M
33.63M
13.76M
Selling, General & Administrative Expenses
95.44M
31.18M
13.67M
2.98M
Selling & Marketing Expenses
54.62M
0
0
0
General & Administrative Expenses
40.81M
31.18M
13.67M
2.98M
Other Expenses
0
0
0
0
Operating Income
-96.92M
-70.99M
-47.3M
-16.74M
Total Other Income/Expenses Net
-3.73M
469k
1.59M
233k
Income Before Tax
-100.66M
-70.52M
-45.71M
-16.5M
Income Tax
3.73M
469k
1.59M
0
Net Income
-104.39M
-70.52M
-45.71M
-16.5M
Basic EPS
-4.01
-2.92
-9.97
-1.83
EPS Diluted
-4.01
-2.92
-9.97
-1.83
Basic Average Shares
26.04M
24.13M
4.59M
9.02M
Diluted Average Shares
26.04M
24.13M
4.59M
9.02M
EBITDA
-96.78M
-70.06M
-45.69M
-16.5M
Retained Earning Schedule
Year
2021
2020
2019
2018
Retained Earnings (Previous Year)
-154.75M
-84.23M
-38.52M
-22.02M
Net Income
-104.39M
-70.52M
-45.71M
-16.5M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-255.41M
-154.75M
-84.23M
-38.52M
Other Distributions
-100.66M
-70.52M
-45.71M
-16.5M
PPE Schedule
Year
2021
2020
2019
2018
Gross PPE
5.4M
1.48M
978k
66k
Annual Depreciation
141k
461k
19k
233k
Capital Expenditure
-1.49M
-700k
-200k
0
Net PPE
6.74M
1.72M
1.16M
-167k
Intangible and Goodwill Schedule
Year
2021
2020
2019
2018
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
